Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis in a psoriasis patient after sequential biologics including extended brodalumab: a case report.

Abstract

Biologic therapies have revolutionized psoriasis management, but they have also raised concerns about potential unusual adverse effects. We think this represents the first detailed case of subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis in a psoriasis patient, confirmed clinically and histopathologically, occurring after 9 months of brodalumab treatment following multiple biologic switches. The patient's development of subcutaneous panniculitis-like T-cell lymphoma during an extended period on brodalumab, compared to other biologics, underscores the need for awareness of potential rare complications associated with this therapy.